SCHEMBL184978

SCHEMBL184978

O=C(O)C(Oc1ccc(Cl)cc1F)c1ccc(S(=O)(=O)N2CCCCC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.65
PPARA Q07869 2/20 0.65
GCK P35557 3/20 0.55
KDM4E B2RXH2 2/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
CYP3A4 P08684 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TSHR P16473 2/20 0.45
POLB P06746 1/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184997 0.90 PPARG (0.63) PPARGPPARAGCKKDM4EL3MBTL1
SCHEMBL184698 0.89 GCK (0.61) PPARGPPARAGCKKDM4EGAA
SCHEMBL184988 0.88 GCK (0.60) PPARGPPARAGCKKDM4EMAPT
SCHEMBL185307 0.86 GCK (0.58) PPARGPPARAGCKMAPTCYP3A4
SCHEMBL184895 0.82 L3MBTL1 (0.54) L3MBTL1ALDH1A1KMT2ALMNAMEN1
SCHEMBL185444 0.79 GCK (0.89) PPARGPPARAGCKKDM4EGAA
SCHEMBL184524 0.79 GCK (0.61) PPARGPPARAGCKALDH1A1KMT2A
SCHEMBL19921743 0.78 GCK (0.51) PPARGPPARAGCKKDM4EGAA
SCHEMBL196130 0.77 GCK (0.57) GCKKDM4EALDH1A1KMT2AHSD17B10
SCHEMBL184891 0.77 GCK (0.49) PPARGPPARAGCKMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA PPARG 329/4885PPARA 289/4885GCK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.